DERMTECH OPERATIONS, INC.
SAN DIEGO, CA

DermTech is the global leader in molecular dermatology, bringing precision medicine to the diagnosis and treatment of skin disease. We market and develop products that facilitate the early detection of skin cancers, assess inflammatory diseases, and customize drug treatments. DermTech analyzes skin biopsy samples collected non-invasively using an adhesive patch rather than a scalpel. Our mission is to transform dermatology by delivering highly accurate and objective information to the clinician to improve care and reduce costs and to pharma partners to support the development of targeted therapeutics. DermTech operates a CLIA licensed laboratory located in the company’s La Jolla, CA headquarters. PRODUCTS John Dobak, MD, has served as Founder and CEO of several venture-backed life science companies in San Diego. Dr. Dobak is the President of the JAKK Group, a life sciences technology accelerator, which has created several companies, including Lithera, INNERCOOL Therapies, and CryoGen/CryoCor. These companies have developed and marketed therapeutics, ranging from endovascular hypothermia to treat cardiac arrest to catheter-based treatments for cardiac arrhythmias. They have been financed by top tier investment firms and have achieved exits through acquisition and an IPO. Dr. Dobak and these companies are the recipients of several awards for entrepreneurship and innovation, including UCSD Connect’s Most Innovative New Product and MIT’s TR 100. Dr. Dobak received a Bachelor’s Degree from UCLA and a Medical Doctorate from UCSD. Dr. Yao has over 16 years of product development and management experience in the biotech industry with a track record of successful development of various molecular diagnostic products, from product idea conception to market launch. Prior to joining DermTech, Dr. Yao has served as VP of Assay Development at Nexogen, Associate Director of R&D at Adnavance Technologies, Principal Scientist at Celula and Senior Staff Scientist at Nanogen. He holds a PhD degree in Biochemistry from Memorial University of Newfoundland in Canada and received post-doctoral research training at the National Institute of Basic Biology (NIBB) in Okazaki (Japan) and at the School of Medicine, University of California, San Diego (UCSD). He has close to 40 publications and owns numerous patents on rapid nucleic acid amplification and detection for diagnostic application. Burkhard Jansen, MD is a melanoma expert with background as a tenured professor of both dermatology and clinical pharmacology with FDA experience. Dr. Jansen has served as founder, director, and senior executive of a number of dermatology and oncology focused life sciences companies, including Novelix, Avienne, and Oncogenex in the US, Canada, and Europe. Dr. Jansen received his medical doctorate and dermatology training from the Universities of Graz and Vienna in Austria, his postdoctoral science training at the University of Minnesota, and his executive business education at UCLA. Sarah Dion comes to DermTech with a successful track record of leading, innovation, development, and product commercialization in many fields of life science, including experience in pharmaceuticals, diagnostics and laboratory services. Her background includes work in research, product development, marketing, and leading a sales organization of over 85 personnel. Prior to DermTech, she held the position of Vice President Commercial Operations at LABS Inc. where she led the commercial team of sales, marketing, IT and client solutions. Mrs. Dion joined LABS after working as Senior Sales Director at Pathway Genomics where the sales team grew revenues and volume by over 2,000% year over year and was recognized by industry magazines as one of the fastest growing companies in the US. She holds a bachelors degree in Chemistry from Covenant College and an MBA from PLNU. James Rock, currently serves as the Vice President of Clinical Operations and Research Contracts. He has over 15 years of experience having worked in clinical and business development capacities including partnering activities, raising capital and product development. He has been instrumental in bring several products to marking including OTC, prescription drugs, and novel in vitro diagnostics. Previously he was Vice President of Clinical Affairs for Trinity Biotech, Director of New Product Development and Interim CEO at Pacific Beach BioSciences, and Director of Clinical Development at MPEX Pharmaceuticals. Mr. Rock holds a BS from the University of Vermont, received his MSc degree from Springfield College, and his MBA from Pepperdine University. PRODUCTS Mr. Jacobs is Managing Director of Jacobs Investment Company, LLC. In addition, Mr. Jacobs serves on the boards of Next Generation Technologies and Fallbrook Technologies and is Chairman of Nutrina, Ltd., a biotechnology company focused on bioactive supplements for infant formulas. Mr. Jacobs is also actively involved with education and philanthropy, serving as Chairman of the Board of Trustees of High Tech High in San Diego and Chair of the Dean’s Advisory Council for Social Sciences at the University of California, San Diego. Mr. Jacobs received his Bachelor of Arts degree in Management Science from the University of California, San Diego. Dr. Peck joined the FDA as Director, Center for Drug Evaluation and Research, in October 1987 and was named Assistant Surgeon General for the United States in October 1990. In 1994, Dr. Peck joined the faculty of the Georgetown University Medical Center, where he is the founding Director of the Center for Drug Development Science (CDDS); in 2004, CDDS became affiliated with the UCSF School of Pharmacy. He obtained his MD from the University of Kansas in 1968, trained in internal medicine and undertook a research fellowship in clinical pharmacology at the University of California, San Francisco. In 1980, Dr. Peck became Director of the Division of Clinical Pharmacology and Professor, Departments of Medicine and Pharmacology, Uniformed Services University, Bethesda, Maryland. In 1999, Commissioner Henney presented him with the FDA Distinguished Alumnus Award. Dr. Peck is currently the Chairman of NDA Partners, LLC.